Article
What Drives Orphan Drug Development?
In this video from The Academy of Managed Care Pharmacy's 25th Annual Meeting & Expo, Matthias Cheung, PhD, FCSHP, FASHP, from Advanced Rx Consulting, LLC, discusses the circumstances and factors that catalyzed the passage of current legislation and regulatory policies for orphan drugs, rare diseases, and ultra-rare diseases.
Matthias Cheung, PhD, FCSHP, FASHP, a principal at Advanced Rx Consulting, LLC, and an adjunct professor of pharmacy practice at the University of the Pacific, Thomas J. Long School of Pharmacy and Health Services, discusses the circumstances and factors that catalyzed the passage of current legislation and regulatory policies for orphan drugs, rare diseases, and ultra-rare diseases.
This video was taken at the Academy of Managed Care Pharmacy's 25th Annual Meeting & Expo in San Diego, CA, on April 5, 2013.
FDA Approves Bimekizumab-Bkzx as Treatment for Hidradenitis Suppurativa
